UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8‑K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 17, 2020
Ra Medical Systems, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware
|
|
001-38677
|
|
38-3661826
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
(760) 804-1648
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on which registered
|
|
Common Stock, par value $0.0001 per share
|
|
RMED
|
|
New York Stock Exchange
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On December 17, 2020, Ra Medical Systems, Inc. (the “Company”) announced that it has received approval to list its common stock, par value $0.0001 per share (the “Common Stock”), on the NYSE American, and provided written notice to the New York Stock Exchange (the “NYSE”) of its intention to list its Common Stock on NYSE American and to simultaneously delist such securities from the NYSE. The Company anticipates that its Common Stock will begin trading on NYSE American at the commencement of trading on December 22, 2020 under its current stock symbol “RMED.” The Company’s Common Stock will continue to trade on the NYSE until the close of trading on December 21, 2020.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
RA MEDICAL SYSTEMS, INC.
|
|
|
|
|
|
|
|
Date: December 17, 2020
|
|
By:
|
|
/s/ Daniel Horwood
|
|
|
|
|
|
Daniel Horwood
|
|
|
|
|
|
General Counsel and Secretary
|
Exhibit 99.1
Ra Medical Systems Announces Transfer of Listing to NYSE American
CARLSBAD, Calif. (December 17, 2020) – Ra Medical Systems, Inc. (NYSE: RMED) , a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, announces that its common stock has been approved for listing on the NYSE American, and the listing will be transferred by the New York Stock Exchange (NYSE).
The Company anticipates that its common stock will begin trading on NYSE American at the commencement of trading on December 22, 2020 and will continue to trade on the NYSE until that time. The Company will retain its current ticker symbol “RMED.”
“We believe the NYSE American is a great fit for our Company as this trading platform more closely reflects our current capital structure,” said Will McGuire, Ra Medical Systems CEO. “We appreciate the ability to maintain our long-term relationship with the NYSE.”
About Ra Medical Systems
Ra Medical Systems commercializes excimer lasers and catheters for the treatment of vascular and dermatological diseases. In May 2017 the DABRA excimer laser system received FDA 510(k) clearance in the U.S. for crossing chronic total occlusions, or CTOs, in patients with symptomatic infrainguinal lower extremity vascular disease with an intended use for ablating a channel in occlusive peripheral vascular disease. The Pharos excimer laser system is FDA-cleared and is used as a tool in the treatment of psoriasis, vitiligo, atopic dermatitis and leukoderma. DABRA and Pharos are both based on Ra Medical’s core excimer laser technology platform and deploy similar mechanisms of action. Ra Medical manufactures DABRA and Pharos excimer lasers and catheters in a 32,000-square-foot facility located in Carlsbad, Calif. The vertically integrated facility is ISO 13485 certified and is licensed by the State of California to manufacture sterile, single-use catheters in controlled environments.
At the Company:
Andrew Jackson
Chief Financial Officer, Ra Medical Systems
760-496-9540
ajackson@ramed.com
Investors:
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com
# # #